MedGenome has taken a majority stake in Gujarat-based Green Cross Genetics Lab, a pathology chain with over three decades of operation. This move expands MedGenome's diagnostic network into western India, where it now controls 17 laboratories and 35 collection centers. The partnership fuses traditional pathology with advanced genomics to reach more patients in underserved areas.
Established Network Meets Cutting-Edge Genomics
Green Cross, founded by Vinod Patel, has built a reputation for reliable diagnostics across Gujarat. Its 17 labs and 35 collection points serve patients through a team of more than 500 professionals, offering over 800 tests under expert oversight. Promoters like Patel will retain leadership as the chain scales up.
MedGenome brings South Asia's largest CAP-accredited multiomics lab to the table. The company applies AI and machine learning to genetic data, aiding clinicians in pinpointing complex diseases. Dr. Vedam Ramprasad, MedGenome's CEO, described the deal as a way to extend affordable omics testing to Tier 2 and Tier 3 cities, building on Green Cross's legacy of trust.
Strategic Synergies for Precision Healthcare
Vinod Patel emphasized the alignment of both firms' commitments to quality. Green Cross's infrastructure and clinical expertise pair with MedGenome's genomic platforms to expand service options nationwide. This integration promises actionable genetic tests alongside routine diagnostics, a step forward in routine clinical practice.
Genomics has transformed disease detection by revealing molecular causes invisible to standard pathology. In India, where chronic conditions like cancer and rare disorders burden healthcare systems, such tools enable earlier interventions. The collaboration addresses access gaps, particularly in regions with limited specialized labs.
Broadening Impact on India's Diagnostic Landscape
The partnership positions genomics for wider adoption in diagnostics, as noted by Express Healthcare. Patients gain from combined networks that deliver precise, data-backed results. MedGenome aims to elevate Indian genomics globally through scalable innovations.
India's diagnostics sector grows amid rising demand for personalized medicine, yet rural and semi-urban areas lag. This investment counters that by embedding advanced testing in established chains, potentially lowering costs and improving outcomes for diverse populations. Future expansions could model similar integrations elsewhere.
